Financial Ratios Bangkok Dusit Medical Services
Stocks
BDMS
TH0264A10Z04
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.40 THB | +0.52% |
|
+1.04% | +0.52% |
| 24/06 | Bangkok Dusit Medical Services Public Company Limited Announces Company Secretary Changes | CI |
| 18/06 | Bangkok Dusit Medical Boosts Residential Project Budget to THB29 Billion | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.71 | 7.86 | 8.28 | 8.66 | 8.14 | |||||
Return on Total Capital | 5.6 | 9.48 | 10.08 | 10.67 | 10.09 | |||||
Return On Equity % | 9.47 | 14.61 | 15.47 | 16.29 | 15.3 | |||||
Return on Common Equity | 9.24 | 14.51 | 15.53 | 16.36 | 15.39 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 33.56 | 37.26 | 37.9 | 37.75 | 37.05 | |||||
SG&A Margin | 20.19 | 18.99 | 19.4 | 19.05 | 19.24 | |||||
EBITDA Margin % | 21.24 | 24.21 | 23.83 | 23.91 | 23.46 | |||||
EBITA Margin % | 13.8 | 18.62 | 18.87 | 19.09 | 18.25 | |||||
EBIT Margin % | 13.38 | 18.27 | 18.5 | 18.7 | 17.81 | |||||
Income From Continuing Operations Margin % | 11.4 | 14.26 | 14.59 | 15.12 | 14.46 | |||||
Net Income Margin % | 10.66 | 13.56 | 14.08 | 14.62 | 14 | |||||
Net Avail. For Common Margin % | 10.66 | 13.56 | 14.08 | 14.62 | 14 | |||||
Normalized Net Income Margin | 8.15 | 10.38 | 10.91 | 11.12 | 10.62 | |||||
Levered Free Cash Flow Margin | 9.09 | 12.71 | 8.99 | 6.99 | 5.77 | |||||
Unlevered Free Cash Flow Margin | 9.7 | 13.13 | 9.33 | 7.24 | 5.96 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.56 | 0.69 | 0.72 | 0.74 | 0.73 | |||||
Fixed Assets Turnover | 0.89 | 1.07 | 1.08 | 1.09 | 1.06 | |||||
Receivables Turnover (Average Receivables) | 9.75 | 9.91 | 9.64 | 9.56 | 9.59 | |||||
Inventory Turnover (Average Inventory) | 25.63 | 27.67 | 27.39 | 27.1 | 23.65 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.54 | 1.35 | 1.28 | 1.07 | 0.98 | |||||
Quick Ratio | 1.36 | 1.22 | 1.13 | 0.94 | 0.81 | |||||
Operating Cash Flow to Current Liabilities | 0.92 | 0.98 | 1.13 | 1.04 | 0.99 | |||||
Days Sales Outstanding (Average Receivables) | 37.45 | 36.84 | 37.87 | 38.28 | 38.05 | |||||
Days Outstanding Inventory (Average Inventory) | 14.24 | 13.19 | 13.33 | 13.5 | 15.43 | |||||
Average Days Payable Outstanding | 24.52 | 24.28 | 24.94 | 25.29 | 25.4 | |||||
Cash Conversion Cycle (Average Days) | 27.17 | 25.75 | 26.27 | 26.49 | 28.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 21.45 | 25.18 | 18.34 | 17.66 | 15.9 | |||||
Total Debt / Total Capital | 17.66 | 20.11 | 15.5 | 15.01 | 13.72 | |||||
LT Debt/Equity | 17.53 | 18.33 | 15.49 | 13.03 | 9.64 | |||||
Long-Term Debt / Total Capital | 14.43 | 14.65 | 13.09 | 11.07 | 8.32 | |||||
Total Liabilities / Total Assets | 31.68 | 33.79 | 31.15 | 31.41 | 30.36 | |||||
EBIT / Interest Expense | 13.67 | 26.87 | 34.56 | 47.19 | 56.55 | |||||
EBITDA / Interest Expense | 22.35 | 36.28 | 45.26 | 61.34 | 75.75 | |||||
(EBITDA - Capex) / Interest Expense | 16.89 | 29.31 | 31.09 | 36.58 | 46.54 | |||||
Total Debt / EBITDA | 1.16 | 1.03 | 0.73 | 0.69 | 0.65 | |||||
Net Debt / EBITDA | 0.38 | 0.38 | 0.35 | 0.36 | 0.38 | |||||
Total Debt / (EBITDA - Capex) | 1.53 | 1.27 | 1.07 | 1.16 | 1.05 | |||||
Net Debt / (EBITDA - Capex) | 0.5 | 0.46 | 0.51 | 0.61 | 0.62 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 9.37 | 22.79 | 9.83 | 7.09 | 3.53 | |||||
Gross Profit, 1 Yr. Growth % | 15.14 | 32.12 | 11.72 | 6.67 | 1.61 | |||||
EBITDA, 1 Yr. Growth % | 17.13 | 31.86 | 8.11 | 7.41 | 1.58 | |||||
EBITA, 1 Yr. Growth % | 31.05 | 50.13 | 11.29 | 8.33 | -1.03 | |||||
EBIT, 1 Yr. Growth % | 32.07 | 51.32 | 11.24 | 8.26 | -1.42 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 11 | 56.11 | 12.4 | 11.15 | -1.03 | |||||
Net Income, 1 Yr. Growth % | 10.01 | 58.85 | 14.03 | 11.35 | -0.87 | |||||
Normalized Net Income, 1 Yr. Growth % | 33.42 | 59.11 | 15.36 | 9.16 | -1.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 10.01 | 58.85 | 14.03 | 11.35 | -0.87 | |||||
Accounts Receivable, 1 Yr. Growth % | 28.17 | 16.24 | 9.79 | 6.01 | 0.23 | |||||
Inventory, 1 Yr. Growth % | 8.07 | 10.29 | 9.43 | 7.59 | 31.46 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -2.45 | 10.87 | 6.31 | 6.93 | 5.22 | |||||
Total Assets, 1 Yr. Growth % | -5.58 | 10.19 | 1.45 | 5.37 | 4.26 | |||||
Tangible Book Value, 1 Yr. Growth % | -5.79 | 8.77 | 7.28 | 5.47 | 6.69 | |||||
Common Equity, 1 Yr. Growth % | -4.62 | 7.2 | 5.97 | 4.81 | 5.86 | |||||
Cash From Operations, 1 Yr. Growth % | 24.65 | 39.18 | 2.53 | 10.19 | 1.73 | |||||
Capital Expenditures, 1 Yr. Growth % | -37.25 | 10.83 | 75.8 | 38.53 | -2.92 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 190.31 | 56.33 | -22.29 | -16.69 | -14.67 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 151.33 | 52.4 | -22.01 | -16.84 | -14.77 | |||||
Dividend Per Share, 1 Yr. Growth % | -18.18 | 33.33 | 16.67 | 7.14 | 33.33 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -5.13 | 16.86 | 16.13 | 8.45 | 5.29 | |||||
Gross Profit, 2 Yr. CAGR % | -6.27 | 26.33 | 21.49 | 9.17 | 4.11 | |||||
EBITDA, 2 Yr. CAGR % | -2.85 | 29.14 | 19.39 | 7.76 | 4.46 | |||||
EBITA, 2 Yr. CAGR % | -4.51 | 48.64 | 29.26 | 9.8 | 3.54 | |||||
EBIT, 2 Yr. CAGR % | -4.84 | 50.06 | 29.74 | 9.74 | 3.31 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -27.18 | 31.63 | 32.46 | 11.71 | 4.88 | |||||
Net Income, 2 Yr. CAGR % | -28.49 | 32.19 | 34.59 | 12.61 | 5.06 | |||||
Normalized Net Income, 2 Yr. CAGR % | -8.03 | 45.7 | 35.48 | 12.21 | 3.89 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -28.82 | 32.19 | 34.59 | 12.61 | 5.06 | |||||
Accounts Receivable, 2 Yr. CAGR % | 1.69 | 22.06 | 12.97 | 7.88 | 3.08 | |||||
Inventory, 2 Yr. CAGR % | 4.29 | 9.18 | 9.86 | 8.51 | 18.93 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 2.59 | 4 | 8.57 | 6.62 | 6.07 | |||||
Total Assets, 2 Yr. CAGR % | -1.97 | 2 | 5.73 | 3.46 | 4.81 | |||||
Tangible Book Value, 2 Yr. CAGR % | 0.86 | 1.23 | 8.02 | 6.51 | 6.08 | |||||
Common Equity, 2 Yr. CAGR % | 0.02 | 1.11 | 6.58 | 5.5 | 5.33 | |||||
Cash From Operations, 2 Yr. CAGR % | 0.05 | 31.72 | 19.46 | 6.43 | 5.88 | |||||
Capital Expenditures, 2 Yr. CAGR % | -26.89 | -16.61 | 39.59 | 56.06 | 15.97 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 42.22 | 125.12 | 10.22 | -19.54 | -15.69 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 35.85 | 106.13 | 9.02 | -19.46 | -15.81 | |||||
Dividend Per Share, 2 Yr. CAGR % | -9.55 | 4.45 | 24.72 | 11.8 | 19.52 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -1.27 | 3.97 | 14.47 | 13.04 | 6.79 | |||||
Gross Profit, 3 Yr. CAGR % | -2.39 | 6.79 | 21.26 | 16.34 | 6.59 | |||||
EBITDA, 3 Yr. CAGR % | -0.93 | 10.35 | 21.71 | 15.26 | 5.66 | |||||
EBITA, 3 Yr. CAGR % | -2.73 | 15.41 | 34.97 | 21.87 | 6.06 | |||||
EBIT, 3 Yr. CAGR % | -2.88 | 15.58 | 35.81 | 22.14 | 5.88 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -4.17 | -6.1 | 24.88 | 24.89 | 7.29 | |||||
Net Income, 3 Yr. CAGR % | -4.78 | -6.69 | 25.84 | 26.3 | 7.93 | |||||
Normalized Net Income, 3 Yr. CAGR % | -5.92 | 10.41 | 34.79 | 26.07 | 7.58 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -5.42 | -6.98 | 25.84 | 26.3 | 7.93 | |||||
Accounts Receivable, 3 Yr. CAGR % | 6.72 | 6.33 | 17.83 | 10.6 | 5.27 | |||||
Inventory, 3 Yr. CAGR % | 3.93 | 6.25 | 9.26 | 9.1 | 15.67 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3.46 | 5.28 | 4.76 | 8.02 | 6.15 | |||||
Total Assets, 3 Yr. CAGR % | -1.28 | 1.93 | 1.82 | 5.66 | 3.73 | |||||
Tangible Book Value, 3 Yr. CAGR % | 8.71 | 3.43 | 3.2 | 7.26 | 6.57 | |||||
Common Equity, 3 Yr. CAGR % | 6.04 | 2.36 | 2.71 | 6.06 | 5.62 | |||||
Cash From Operations, 3 Yr. CAGR % | -0.55 | 11.69 | 21.16 | 16.39 | 4.84 | |||||
Capital Expenditures, 3 Yr. CAGR % | -17.65 | -16.01 | 6.93 | 39.23 | 33.22 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 13.15 | 52.27 | 57.92 | 0.4 | -17.95 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 10.34 | 46.12 | 49.09 | -0.38 | -17.93 | |||||
Dividend Per Share, 3 Yr. CAGR % | 12.04 | 2.94 | 8.37 | 18.56 | 18.56 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 1.86 | 5.02 | 5.71 | 5.74 | 10.71 | |||||
Gross Profit, 5 Yr. CAGR % | 2.01 | 6.91 | 7.57 | 7.73 | 14.09 | |||||
EBITDA, 5 Yr. CAGR % | 2.78 | 7.78 | 8.4 | 9.31 | 14.49 | |||||
EBITA, 5 Yr. CAGR % | 2.2 | 10.37 | 11.54 | 13.13 | 21.39 | |||||
EBIT, 5 Yr. CAGR % | 2.09 | 10.5 | 11.68 | 13.21 | 21.73 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -0.65 | 4.62 | 9.08 | 0.65 | 16.43 | |||||
Net Income, 5 Yr. CAGR % | -1.1 | 4.29 | 9.36 | 0.6 | 17.05 | |||||
Normalized Net Income, 5 Yr. CAGR % | -0.33 | 9.79 | 8.85 | 11.13 | 21.46 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -1.6 | 3.76 | 8.91 | 0.41 | 17.05 | |||||
Accounts Receivable, 5 Yr. CAGR % | 8.33 | 9.19 | 9.18 | 6.95 | 11.69 | |||||
Inventory, 5 Yr. CAGR % | 5.75 | 4.97 | 6.26 | 7.15 | 13.03 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 7.89 | 5.05 | 5.47 | 5.81 | 5.28 | |||||
Total Assets, 5 Yr. CAGR % | 3.72 | 2.91 | 1.47 | 2.54 | 3.03 | |||||
Tangible Book Value, 5 Yr. CAGR % | 12 | 10.14 | 8.43 | 4.65 | 4.4 | |||||
Common Equity, 5 Yr. CAGR % | 8.52 | 7.34 | 6.26 | 3.6 | 3.79 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.19 | 13.14 | 7.02 | 9.56 | 14.86 | |||||
Capital Expenditures, 5 Yr. CAGR % | -14.11 | -22.04 | 1.7 | 7.61 | 10.46 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 58.67 | 14.78 | 14.46 | 17.98 | 22.86 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 43.38 | 19.47 | 12.11 | 15.14 | 18.62 | |||||
Dividend Per Share, 5 Yr. CAGR % | 9.18 | 10.76 | 16.95 | 6.4 | 12.7 |
- Stock Market
- Stocks
- BDMS Stock
- Financials Bangkok Dusit Medical Services
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















